Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) is dated January 17, 2020. The report addresses a specific corporate governance event regarding the company's continued listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial metric disclosed is the market value of listed securities, which the company confirmed met the threshold of at least $35 million to satisfy Nasdaq listing requirements.
Material Changes
The primary material change reported is the resolution of a listing deficiency. Previously, on August 16, 2019, Nasdaq notified the company that its stockholders' equity did not meet the continued listing requirement under Rule 5550(b)(1). On January 17, 2020, Nasdaq confirmed that the company regained compliance by meeting the alternative requirement of maintaining a market value of listed securities of at least $35 million.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks. The document focuses solely on the historical timeline of the compliance issue: the initial notice in August 2019, the submission of a compliance plan in September 2019, the extension granted in October 2019, and the final confirmation of compliance in January 2020.
Investor Verification Checklist
- Verify the current market capitalization of Bionano Genomics, Inc. to ensure it remains above the $35 million threshold required for continued listing.
- Review the company's most recent Form 10-Q or 10-K to assess the status of stockholders' equity, which was the original cause of the listing deficiency.
- Confirm that no further correspondence from Nasdaq regarding listing compliance has been issued since January 17, 2020.